Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
MyeloMATCH trial: what clinicians have said so far
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- NCT06577441 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on MyeloMATCH yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MyeloMATCH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on Bluesky | |
| 1 post on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Enasidenib
- Arms
- Regimen 1 (ASTX727) · Active comparator
- Regimen 2 (ASTX727, enasidenib) · Experimental
- Enrollment
- 54 (estimated)
- Primary outcomes
- Complete response (CR) rate
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 12, 2025
- Primary completion
- Mar 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06577441 · updated Nov 4, 2026